KRAS and metastatic colorectal cancer: Promising results have been also described in metastatic colorectal cancer where this VEGFR2 polymorphism was significantly associated with increased PFS and OS in multivariate analysis in metastatic patients treated with first-line oxaliplatin-based chemotherapy regardless the KRAS mutational status [29].